Independent
Tenure on this board
1.8 yrs
Meeting calendar
CAMP · Annual meeting · Wednesday, June 10, 2026
Camp4 Therapeutics Corp
3 nominees · 3 ballot items.
Election of three Class II directors; Ratification of Ernst & Young LLP as independent auditors; Approval of Amendment No.1 to the 2024 Equity Incentive Plan (amending evergreen calculation to include pre-funded warrants).
Market cap
$234M
1Y TSR
+142.9%
Board grade
C-
Record date
Apr 13, 2026
Filing
DEF 14A
Meeting concluded · Jun 10, 2026
Follow how the vote landed and what changed on Camp4 Therapeutics Corp’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot3
- 1
Election of Directors (Class II
ManagementBoard: FORElect Steven Holtzman, Murray Stewart, DM FRCP, and Richard Young, PhD as Class II directors for three-year terms.
- 2
Ratification of Appointment of Independent Registered Public Accounting Firm
ManagementBoard: FORRatify the appointment of Ernst & Young LLP as the company’s independent registered public accounting firm for fiscal year ending December 31, 2026.
- 3
Approval of Amendment No. 1 to the CAMP4 Therapeutics Corporation 2024 Equity Incentive Plan
ManagementBoard: FORApprove amendment to the 2024 Equity Incentive Plan to modify the evergreen provision to include pre-funded warrants in the calculation of outstanding shares for annual share reserve increases.
More detail
The Board seeks shareholder approval to amend the 2024 Equity Incentive Plan’s evergreen formula to include pre-funded warrants in the calculation of outstanding shares used to determine the annual automatic share reserve increase. Management’s rationale is that the company issued pre-funded warrants in its September 2025 private placement in lieu of common stock to certain investors, which meant the existing evergreen calculation—based solely on issued and outstanding common stock—did not reflect capital raised via pre-funded warrants, thereby creating a disproportionately smaller annual increase in the share reserve. The amendment is narrowly targeted (only the evergreen formula is changed), and the Board and compensation committee, with benchmarking support from Alpine, concluded it is reasonable and necessary to maintain competitive equity grant capacity for recruiting and retention. Approval would slightly increase the annual share pool (Company estimates an additional ~300,187 shares based on April 1, 2026 figures) and would apply prospectively beginning with the annual increase on January 1, 2027; failure to approve could constrain equity grant flexibility, potentially forcing alternative, less alignment-creating compensation methods. The proposal raises standard governance considerations—dilution, alignment, and whether increases are commensurate with capital raised by warrant issuances—and is management-recommended with the board’s reasoning explained in the proxy.
Director elections
Nominees on the ballot3
Independent
Tenure on this board
1.4 yrs
Also a director at
X4 Pharmaceuticals Inc (XFOR)
Independent
Tenure on this board
1.8 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | JANUS HENDERSON GROUP PLC | 12.1% | 6,307,636 | $28M |
| 2 | 5AM Venture Management, LLC | 11.3% | 5,869,091 | $26M |
| 3 | Vivo Capital, LLC | 8.2% | 4,246,568 | $19M |
| 4 | FMR LLC | 7.4% | 3,817,479 | $17M |
| 5 | BALYASNY ASSET MANAGEMENT L.P. | 5.1% | 2,632,437 | $12M |
| 6 | Enavate Sciences GP, LLC | 4.2% | 2,190,920 | $10M |
| 7 | a16z Capital Management, L.L.C. | 4.1% | 2,125,339 | $9M |
| 8 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 3.8% | 1,960,784 | $9M |
| 9 | Trails Edge Capital Partners, LP | 3.7% | 1,939,563 | $9M |
| 10 | VANGUARD CAPITAL MANAGEMENT LLC | 3.0% | 1,534,768 | $7M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Camp4 Therapeutics Corp’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Anavex Life Sciences CorpAVXL
Annual meeting·Sep 24, 2026·$303M
Simulations Plus IncSLP
Special meeting·Aug 27, 2026·$370M
Canopy Growth CorpCGC
Annual meeting·Sep 25, 2026·$427M
Ocugen IncOCGN
Special meeting·Sep 21, 2026·$458M
Artiva Biotherapeutics IncARTV
Annual meeting·Sep 8, 2026·$553M
Replimune Group IncREPL
Annual meeting·Sep 15, 2026·$1.3B
Reference
Frequently asked questions
- When is the Camp4 Therapeutics Corp 2026 annual meeting?
- Camp4 Therapeutics Corp (CAMP) holds its 2026 annual shareholder meeting on Wednesday, June 10, 2026.
- What is the record date for the Camp4 Therapeutics Corp 2026 meeting?
- The record date for the Camp4 Therapeutics Corp 2026 meeting is Monday, April 13, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Camp4 Therapeutics Corp's 2026 meeting?
- The board is presenting 3 director nominees at the Camp4 Therapeutics Corp 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Camp4 Therapeutics Corp 2026 meeting?
- Shareholders will vote on 3 proposals at the Camp4 Therapeutics Corp 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.